Many new products showing up on mellowhope website including blood products. remember that merger with Hb products in canada. makes you wonder.
Singapore, Nov 23, 2010: Hard to Treat Diseases (HTDS), China, focused on the development and licensing of proprietary technologies, has announced that it is merging with Canadian biotech company, Hb Products. The merger is said to be proceeding well. Dealing with blood transfusion products, Hb is involved in validating a product that will reduce the major side effects related to transfusions of donated blood or hemoglobin-based blood substitutes.
Hb Products focuses on treatment of serious harmful side effects existing with the use of stored donor blood, focusing specifically on solving the loss of Nitric Oxide (NO) from the recipients' blood, which creates a hazardous condition called vasoconstriction.
According to HTDS, the market for these blood products is relatively untapped and highly competitive. Due to the potential market for blood substitutes and the shortfall of available donor blood, several pharma companies have attempted to gain FDA approval for their products, but none have succeeded as of yet. Hb Products plans to demonstrate in pre-clinical tests that its product can circumvent the loss of NO from blood, and improve shelf life of stored blood for up to 42 days.
The market value for blood transfusions in the North American market is currently in excess of $14 billion. HTDS sees Hb Products as a perfect fit, alongside their current medical subsidiaries, Shenzhen Mellow Hope Pharm Industrial and Slavica Biochem.